Louisiana Administrative Code › Title 48 - PUBLIC HEALTH-GENERAL › Part V - Preventive Health Services › Subpart 31 - Louisiana Tumor Registry › Chapter 85 - Statewide Tumor Registry Program › Section V-8502 - Background

Current through Register Vol. 50, No. 6, June 20, 2024
A. In December
				  1971, President Richard Nixon signed the National Cancer Act ( P.L. 92-218).
				  As a result of this act, the Surveillance, Epidemiology and End Results (SEER)
				  Program, a national cancer surveillance program within the National Cancer
				  Institute, was established. Data on cancer incidence and survival were
				  collected in selected states and regions, beginning with cases diagnosed on
				  January 1, 1973. The importance of cancer registration was subsequently
				  reinforced by the passage of federal legislation in 1992 (Public Law
				  102-515) establishing the National Program of
				  Cancer Registries within the CDC. Louisiana participates in both cancer
				  surveillance programs.
B. Acts No.
				  1197 of the 1995 Louisiana Legislative Session clarified the cancer-reporting
				  responsibilities of health care professionals and institutions, provided for
				  intervention in cases of noncompliance, reinforced the confidentiality
				  requirements to protect participants from civil liability, authorized the
				  exchange of cancer incidence data with other states, and provided for related
				  matters.
C. Acts No. 1138 §2
				  of the 1995 Session transferred the Louisiana Tumor Registry program and the
				  Louisiana Cancer and Lung Trust Fund Board to the Board of Supervisors of the
				  Louisiana State University Agricultural and Mechanical College, to be
				  administered by the Louisiana State University Health Sciences Center at New
				  Orleans.
D. Acts No. 197 of the
				  2001 Regular Legislative Session replaced "Secretary of the Department of
				  Health and Hospitals" and "Secretary" with "President of the Louisiana State
				  University System, or his designee" or "President" and replaced "office of
				  public health in the Department of Health and Hospitals" with "office of the
				  President." It also mandated the reporting of follow-up information and
				  confirmed the ability of the LTR to release data to qualified researchers and
				  other state cancer registries.
E.
				  Acts No. 225 of the 2003 Regular Legislative Session added benign and
				  borderline tumors of the brain and central nervous system to the reportablity
				  list and authorized the LTR to cooperate with other designated national and
				  international cancer surveillance programs.
F. Acts No. 373 of the 2017 Regular
				  Legislative Session requires LTR, within the confines of federal privacy laws,
				  to provide diagnostic, treatment and follow-up information for a patient at the
				  request of a physician or medical facility. It also requires LTR to continue to
				  cooperate with Office of Public Health of the Department of Health (LOPH) in
				  the implementation of a program of cancer investigation and intervention, if
				  funding is available, and on evaluation of programs. It changes the smallest
				  level of data released by the LTR to the census tract, if it does not violate
				  suppression rules or federal privacy laws. If a data request is denied by
				  LSUHSC-New Orleans Institutional Review Board (IRB), the requestor must be
				  given notice in writing of the reason. The LTR Research Committee is expanded
				  to include more qualified members. The annual report is now required to be sent
				  to more governmental entities and the governing body of each parish, as well as
				  LTR creating a mechanism for individuals to be notified when it is published on
				  its website.
AUTHORITY NOTE:
					 Promulgated in accordance with
					 R.S.
					 40:1105.3(7).